A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg After 8 Week Treatment in Patients With Mild-to-moderate Systolic Hypertension.
Phase of Trial: Phase II
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Sacubitril (Primary) ; Sacubitril/valsartan; Valsartan
- Indications Essential hypertension
- Focus Therapeutic Use
- Acronyms RATIO
- Sponsors Novartis; Novartis Pharmaceuticals
- 01 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Jan 2011 New trial record